BioPharma Resources

Drug Trial Radar · NCT07516132

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

A Phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

850

Planned (sponsor's estimate)

Start

Apr 27, 2026

Primary completion

Aug 1, 2030

Study completion Aug 1, 2030

Sponsor

Lead sponsor
Ocular Therapeutix, Inc.Industry
Sponsor type
Industry
Collaborators
Fortrea; Duke Reading Center
First posted
Apr 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

  • OTX-TKIDrug

    Intravitreal Injection of OTX-TKI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs) from Baseline (Day 1) through Week 144Time frame: from Baseline (Day 1) through Week 144
  2. Proportion of participants with severe vision loss (defined as ≥ 30 Early Treatment Diabetic Retinopathy Study [ETDRS] letters loss) from Baseline (Day 1) through Week 144Time frame: from Baseline (Day 1) through Week 144

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • California Retina Consultants (CRC)

    Bakersfield, California · Recruiting

  • California Retina Consultants (CRC)

    Santa Barbara, California · Recruiting

  • Retina Group of New England

    Waterford, Connecticut · Recruiting

  • Retina Group of Florida - Fort Lauderdale

    Fort Lauderdale, Florida · Recruiting

  • Cumberland Valley Retina Associates

    Hagerstown, Maryland · Recruiting

  • Mid Atlantic Retina Specialists

    Hagerstown, Maryland · Recruiting

  • Palmetto Retina Center

    West Columbia, South Carolina · Recruiting

  • Austin Retina Associates

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.